HK Stock Price Fluctuated | SCICLONE PHARMA (06600) rose nearly 6% again recently, reaching an agreement with Menarini on Orserdu's licencing and cooperation in China.

In early trading, SCICLONE PHARMA (06600) rose nearly 6%, with a cumulative increase of over 20% this month. As of the time of writing, it rose 5.58% to HKD 12.48, with a turnover of HKD 18.05 million. In terms of news, SCICLONE PHARMA recently announced an agreement with Menarini to obtain the exclusive development and commercialization rights for Elacestrant (trade name: Orserdu) in China. Elacestrant is the world's first oral SERD (selective estrogen receptor degrader) drug to be launched globally. CICC predicts that Scisen will conduct related clinical trials domestically, and is expected to start the listing application as early as 2025-2026. In addition, according to the company's official website, SCICLONE PHARMA, Shanghai Pharma Holdings, and Menarini signed a trilateral strategic cooperation declaration in October 2023. In addition to Oeserdu, the company has previously reached a product development agreement with Menarini for Vaborem. It is recommended to pay attention to the progress of the cooperation between the two parties.